Telix Resubmits Brain Cancer Imaging NDA (TLX101-Px) to FDA, Addressing Prior Concerns
TLX sits 24% above its 52-week low of $6.28.
Summary
Telix Pharmaceuticals has resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer). The company states that the resubmission includes additional data and statistical analysis, which it believes appropriately addresses the Complete Response Letter previously issued by the FDA. This is a significant positive step for Telix, as TLX101-Px has been granted Orphan Drug and Fast Track designations, highlighting its potential to address a critical unmet medical need in brain cancer diagnosis. This development advances a key pipeline candidate towards potential market approval. Investors will now monitor for FDA acceptance of the resubmission and the subsequent announcement of a PDUFA date.
At the time of this announcement, TLX was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $6.28 to $20.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.